viel lari fari dabei

jeder ml minox auf die haut aufgetragen ist minox retard oral und über zig stunden, wenn man es nicht auswäscht

auf "pure drug solution", ohne emulsion schickimicki achten

https://www.researchgate.net/figure/n-vitro-drug-release-profiles-of-minoxidil-formulations-F8-F14meanSD-n3_fig2_286006983


man kann sich auch 5x täglich 0,33mg minox verabreichen, mit einer spray flasche...1 pump 0,33mg

At a dose of 8.5 mg twice daily (BID) for 4 months, VDPHL01 (N=20) was compared with IR oral minoxidil (5 mg once daily for 6 months, N=33) and the topical formulation (5% solution BID for 6 months, N=34) in a retrospective phase 2 trial.

Endpoints included the mean blinded Investigator Global Assessment (IGA) and the proportion of patients achieving a ≥ 2-point improvement on the 7-point Likert scale (–3 to +3), together with the rate of correct identification of baseline findings, as investigators evaluated images of male patients’ hair status without knowing which were baseline and follow-up.

The highest accuracy in distinguishing frontal and vertex views was observed in the VDPHL01 group, with 97.5% and 96.2%, respectively. This suggests an easier-to-identify improvement from baseline compared to IR oral minoxidil (72.9% and 72.3%) and topical minoxidil (60.3% and 49.6%). Mean IGA improvement for the frontal and vertex views was significantly greater with VDPHL01 compared to both other formulations (P<0.001). Mean improvement scores were 2.02 (frontal) and 2.05 (vertex) for VDPHL01, while IR oral minoxidil or topical minoxidil reached frontal and vertex results of 0.59 and 0.53 or 0.29 and 0.02, respectively.

Ich probiers aktuell damit, flüssiges Minoxidil in Wasser in einer Trinkflasche über den Tag verteilt zu trinken, um die Dosis zu verteilen.

VDPHL01 scheint in den Studien schon einen größeren Unterschied auszumachen gegenüber topischem Minoxidil:
https://conferences.medicom-publishers.com/specialisation/dermatology/eadv-2025/extended-release-oral-minoxidil-a-rising-star-in-the-treatment-of-androgenic-alopecia/
Zitat:

At a dose of 8.5 mg twice daily (BID) for 4 months, VDPHL01 (N=20) was compared with IR oral minoxidil (5 mg once daily for 6 months, N=33) and the topical formulation (5% solution BID for 6 months, N=34) in a retrospective phase 2 trial.

Zitat:

Endpoints included the mean blinded Investigator Global Assessment (IGA) and the proportion of patients achieving a ≥ 2-point improvement on the 7-point Likert scale (–3 to +3), together with the rate of correct identification of baseline findings, as investigators evaluated images of male patients’ hair status without knowing which were baseline and follow-up.

The highest accuracy in distinguishing frontal and vertex views was observed in the VDPHL01 group, with 97.5% and 96.2%, respectively. This suggests an easier-to-identify improvement from baseline compared to IR oral minoxidil (72.9% and 72.3%) and topical minoxidil (60.3% and 49.6%). Mean IGA improvement for the frontal and vertex views was significantly greater with VDPHL01 compared to both other formulations (P<0.001). Mean improvement scores were 2.02 (frontal) and 2.05 (vertex) for VDPHL01, while IR oral minoxidil or topical minoxidil reached frontal and vertex results of 0.59 and 0.53 or 0.29 and 0.02, respectively.

Zu Deutsch: Das Untersuchungsteam musste ohne Beschriftung Vorher- von Nachher-Bildern unterscheiden. Bei VPDHL01 gelang das wesentlich besser (97% vs 72% vs ~50%, quasi geraten) als bei oralem oder topischem Minoxidil.
Kleine Studie, Interessenskonflikte, hohe Dosis (2x 8.5mg/d), etc, aber wenns unterm Strich so einen riesigen Unterschied macht lohnt sich das schon.

Sicherheit:  Das Medikament war generell gut verträglich
Keine schwerwiegenden behandlungsbedingten Nebenwirkungen, insbesondere keine Herzprobleme

gibt es auch eine Konzentration/zeit daten für blutspiegel?